Header Image

Genetics and novel treatments

A novel NCSTN gene mutation in a Japanese family with hidradenitis
suppurativa (abstract ID 36)

Adalimumab in Hurley II moderate-severe HS patients: Single center
experience regarding disease non progression (abstract ID 61)

Ixekizumab restores clinical response in patients with secondary loss of
efficacy from adalimumab: results of a case series of 10 patients with
hidradenitis suppurativa (abstract ID 107)

Baseline characteristics and burden of disease in patients with
moderate to severe hidradenitis suppurativa enrolled in the SOLACE
study – Final analysis (abstract 111)

Genome-wide association study of hidradenitis suppurativa in a multiethnic cohort Atlas (abstract ID 128)

Decrease of pain and exacerbations by IFX-1 in severe hidradenitis
suppurativa:An analysis using matched comparators (abstract ID 130)

Adalimumab in conjunction with surgery in patients with moderate to
severe hidradenitis suppurativa: baseline characteristics from a phase
4, double-blind, randomized, placebo-controlled study (abstract ID 132)

Variability of TNFα expression in hidradenitis suppurativa
(abstract ID 142)

Lack of association of ATG16L1 single nucleotide polymorphisms on
predisposition and severity of hidradenitis suppurativa (abstract 163)